Most Read Articles
Audrey Abella, 30 Apr 2019
Nonalcoholic fatty liver disease (NAFLD, or steatosis) was prevalent in a substantial number of young adults, suggesting an imminent public health crisis if left undiagnosed and untreated, according to data from a large UK trial presented at ILC 2019.
Roshini Claire Anthony, 02 May 2019

Patients with non-alcoholic steatohepatitis (NASH) may benefit from treatment with a 25 mg/day dose of obeticholic acid, according to the interim analysis of the phase III REGENERATE* study presented at the International Liver Congress (ILC 2019).

Roshini Claire Anthony, 29 Apr 2019

Adults with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) who progress to advanced liver disease have an elevated risk of mortality compared with non-progressors, according to two separate studies conducted in Germany and France and presented at the International Liver Congress (ILC 2019).

Roshini Claire Anthony, 07 May 2019

The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress (ILC 2019).

Obesity ups risk of acute chronic liver failure in decompensated cirrhosis patients

26 Aug 2018
A higher than normal BMI is often a risk factor for many long-term health problems such as diabetes, hypertension, joint, heart and even liver problems.

In patients with decompensated cirrhosis, class III obesity increases the risk of acute on chronic liver failure (ACLF) development, a recent study has found.

Drawing from the United Network for Organ Sharing database, researchers identified 100,382 eligible participants, of whom 63,712 were nonobese (mean age 53.10±11.0 years; 62.9 percent male), 32,605 were class I–II obese (mean age 54.6±8.9 years; 63.8 percent male) and 4,065 were class III obese (mean age 52.6±9.1 years; 53.7 percent male).

At the time of liver transplantation, 7,630 patients had ACLF, of whom 4,688 were nonobese, 2,587 were class I–II obese and 355 were class III obese. Kaplan-Meier analysis revealed that those with class III obesity were significantly more likely to develop ACLF (p<0.001).

Multivariable Cox proportional hazards regression analysis further confirmed that class III obesity was a significant risk factor for ACLF (hazard ratio [HR], 1.24; 95 percent CI, 1.09–1.41; p<0.0001). The same was true for class I–II obesity (HR, 1.12; 1.05–1.19; p<0.001).

Other factors that significantly correlated with ACLF included older age, hepatitis C infection, ascites, alcoholic liver disease and hepatic encephalopathy.

Obesity was also associated with organ failure. While renal insufficiency was comparable between patient groups, renal failure was progressively more prevalent with increasing obesity class (p<0.001), and coagulation failure was most common in patients with class I–II obesity (51.3 percent). In contrast, liver failure as a component of ACLF was inversely correlated with obesity class.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 30 Apr 2019
Nonalcoholic fatty liver disease (NAFLD, or steatosis) was prevalent in a substantial number of young adults, suggesting an imminent public health crisis if left undiagnosed and untreated, according to data from a large UK trial presented at ILC 2019.
Roshini Claire Anthony, 02 May 2019

Patients with non-alcoholic steatohepatitis (NASH) may benefit from treatment with a 25 mg/day dose of obeticholic acid, according to the interim analysis of the phase III REGENERATE* study presented at the International Liver Congress (ILC 2019).

Roshini Claire Anthony, 29 Apr 2019

Adults with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) who progress to advanced liver disease have an elevated risk of mortality compared with non-progressors, according to two separate studies conducted in Germany and France and presented at the International Liver Congress (ILC 2019).

Roshini Claire Anthony, 07 May 2019

The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress (ILC 2019).